Fri, Mar 6, 2015, 3:45 PM EST - U.S. Markets close in 15 mins.


% | $
Quotes you view appear here for quick access.


  • misterrightnumber1 misterrightnumber1 Oct 30, 2006 8:54 PM Flag

    these longs dont understand basic finance

    SVNT revenues have been cut more than half from 132 mil in 2003 to under 55 mil in 2006

    They are a one product company and even that product is in serious jeopardy from Barr Labs who is challenging their patent.

    If Barr Labs is sucessful and their current product does not have a sucessful phase 3 outcome, then they are basically a penny stock with no income

    How could someone ask such a stupie question about insider buying

    which person who know anything about this company and had half a brain would buy this stock given its enormous risks

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • With just an orphan indication SVNT will double the "top" sales # you indicated. With broader approval it could go up 4-7 fold. The past is small. The future is big. Wake up.

    • Like many others before you, you still don't get it. SVNT = Puricase + Cash. Oxandrin's 60M or so in sales will continue to pay our bills for as long as we are lucky to have it. Since we live in the US and not China, I'm very sure the FDA will take its serious time (at least 2 years is my est) to carefully rule in regard to SVNT's 5 Oxandrin patents which have yet to expire. Regarding Puricase, I believe based on the fact that P2 data was very good and the fact that the P3 SPA endpoints are indentical to P2 except in regard to length of drug use and special focus on elimination of gout tophi,that P3 will be a slam dunk. That said, I firmly believe Puricase will sail through for its orphan indication especially because of the *huge patient need (*50-100K in both the US & EU, and Asia as well). If one multiplies just a fraction of these #s by 10-14K/yr, the top-line # is enormous, and mind you, this assumes no other indications. If Clement today(I hope) again positively talks about the P2 patients who have been on longterm therapy and STILL have no visible signs of gout tophi,we should see a nice pop in the stock. In short, 40+ years is a long time to be without effective treatment options and febuxostat unfortunately -based on the data- falls very short for many patients. ThinkEquity and Pacific Growth should revise their #s upward today or in the coming days.

    • Misterrightnumber savient would not have sold rosemont if they felt that puricase was money in the bank. You have the wrong number.

      • 1 Reply to moemony_51
      • Can't agree with you. Selling Rosemont is exactly what they were advised to do. It makes a clean buyout package and will result in higher bids. The investment bank will make a killing. Insiders will make a killing. And retail trade will ride gravy train all the way to the bank. If you are nervous you can take some of the risk out by buying some puts.

        When the dice roll in 07, SVNT will come up 11!

    • Snooze?? Is that you hiding behind a bad foreign accent?

0.00190.0000(0.00%)May 30 3:56 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.